AbbVie appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors
Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director
Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Subscribe To Our Newsletter & Stay Updated